Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) CFO Xiaofeng Ye sold 5,667 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total value of $80,754.75. Following the completion of the transaction, the chief financial officer directly owned 147,757 shares in the company, valued at approximately $2,105,537.25. This trade represents a 3.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Xiaofeng Ye also recently made the following trade(s):
- On Monday, August 24th, Xiaofeng Ye sold 6,000 shares of Adlai Nortye stock. The stock was sold at an average price of $13.98, for a total transaction of $83,880.00.
Adlai Nortye Trading Up 9.6%
NASDAQ:ANL opened at $15.06 on Thursday. The company has a current ratio of 9.55, a quick ratio of 0.65 and a debt-to-equity ratio of 0.04. Adlai Nortye Ltd. Sponsored ADR has a twelve month low of $0.88 and a twelve month high of $17.25. The company has a fifty day moving average of $12.00 and a 200-day moving average of $11.16.
Institutional Investors Weigh In On Adlai Nortye
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald started coverage on shares of Adlai Nortye in a report on Monday, June 22nd. They set an “overweight” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a research note on Tuesday, July 14th. JonesTrading started coverage on Adlai Nortye in a research report on Thursday, May 14th. They issued a “buy” rating and a $22.00 target price for the company. Wall Street Zen raised Adlai Nortye from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Finally, Oppenheimer started coverage on Adlai Nortye in a report on Thursday, May 28th. They issued an “outperform” rating and a $32.00 price target on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Adlai Nortye has an average rating of “Moderate Buy” and a consensus target price of $24.25.
View Our Latest Research Report on ANL
Adlai Nortye Company Profile
Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
Featured Stories
- Five stocks we like better than Adlai Nortye
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
